-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Amphastar Pharma, Lowers Price Target to $30

Benzinga·02/27/2026 16:36:14
Listen to the news
Wells Fargo analyst Benjamin Burnett maintains Amphastar Pharma (NASDAQ:AMPH) with a Overweight and lowers the price target from $34 to $30.